EA200702468A1 - Новые производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов - Google Patents

Новые производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов

Info

Publication number
EA200702468A1
EA200702468A1 EA200702468A EA200702468A EA200702468A1 EA 200702468 A1 EA200702468 A1 EA 200702468A1 EA 200702468 A EA200702468 A EA 200702468A EA 200702468 A EA200702468 A EA 200702468A EA 200702468 A1 EA200702468 A1 EA 200702468A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
application
metabotropic glutamate
positive allosteric
glutamate receptors
Prior art date
Application number
EA200702468A
Other languages
English (en)
Other versions
EA015263B1 (ru
Inventor
Пиерджилиано Бугада
Стефания Гаглиарди
Эммануэль Ле Поул
Винсент Матель
Джиованни Паломби
Джен-Филиппе Рошер
Original Assignee
Аддекс Фарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аддекс Фарма Са filed Critical Аддекс Фарма Са
Publication of EA200702468A1 publication Critical patent/EA200702468A1/ru
Publication of EA015263B1 publication Critical patent/EA015263B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Настоящее изобретение относится к новым соединениям, которые представляют собой производные оксадиазола формулы (I) в которой значения В, Р, Q, W, Rи Rопределены в описании. Соединения согласно настоящему изобретению пригодны для предотвращения или лечения расстройств центральной или периферической нервной системы, а также других расстройств, регулируемых рецепторами mGluR5.
EA200702468A 2005-05-18 2006-05-17 Производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов EA015263B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1
PCT/IB2006/001674 WO2006123249A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
EA200702468A1 true EA200702468A1 (ru) 2008-06-30
EA015263B1 EA015263B1 (ru) 2011-06-30

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702468A EA015263B1 (ru) 2005-05-18 2006-05-17 Производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов

Country Status (17)

Country Link
US (1) US20090197897A1 (ru)
EP (1) EP1896463A2 (ru)
JP (1) JP2008540634A (ru)
KR (1) KR20080031676A (ru)
CN (1) CN101218232B (ru)
AU (1) AU2006248649B2 (ru)
BR (1) BRPI0610681A2 (ru)
CA (1) CA2608012A1 (ru)
EA (1) EA015263B1 (ru)
GB (1) GB0510142D0 (ru)
IL (1) IL187190A0 (ru)
MX (1) MX2007014405A (ru)
NO (1) NO20076479L (ru)
NZ (1) NZ564253A (ru)
UA (1) UA92496C2 (ru)
WO (1) WO2006123249A2 (ru)
ZA (1) ZA200710277B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
AU2010239253A1 (en) * 2009-04-23 2011-11-24 Merck Sharp & Dohme Corp. 2-alkyl piperidine mGluR5 receptor modulators
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
ES2610362T3 (es) * 2011-01-25 2017-04-27 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2016153023A1 (ja) * 2015-03-25 2016-09-29 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
WO2020154431A1 (en) * 2019-01-25 2020-07-30 Lynch Kevin R Inhibitors of spinster homolog 2 (spns2) for use in therapy
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
EP1119553A1 (en) * 1998-10-07 2001-08-01 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
AU5891600A (en) * 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
DK1210344T3 (da) * 1999-08-19 2006-03-06 Nps Pharma Inc Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister
WO2001054503A1 (en) * 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives
NZ527691A (en) * 2001-02-21 2007-01-26 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
AU2002337498B2 (en) * 2001-09-21 2006-08-10 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
EP1581525A2 (en) * 2002-08-09 2005-10-05 AstraZeneca AB Compounds having an activity at metabotropic glutamate receptors
CN1694703A (zh) 2002-09-06 2005-11-09 詹森药业有限公司 吲哚基衍生物在制备治疗变应性鼻炎的药物中的用途
CA2517629C (en) * 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1716143A1 (en) * 2004-02-18 2006-11-02 AstraZeneca AB Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
AR051823A1 (es) * 2004-09-29 2007-02-14 Mitsubishi Pharma Corp Derivados de piridinil-pirimidonas
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
AU2006248649B2 (en) 2012-04-26
NO20076479L (no) 2008-01-29
UA92496C2 (ru) 2010-11-10
NZ564253A (en) 2011-04-29
US20090197897A1 (en) 2009-08-06
GB0510142D0 (en) 2005-06-22
EA015263B1 (ru) 2011-06-30
CA2608012A1 (en) 2006-11-23
WO2006123249A3 (en) 2007-02-08
EP1896463A2 (en) 2008-03-12
KR20080031676A (ko) 2008-04-10
CN101218232B (zh) 2012-06-27
WO2006123249A2 (en) 2006-11-23
BRPI0610681A2 (pt) 2010-07-20
IL187190A0 (en) 2008-02-09
JP2008540634A (ja) 2008-11-20
AU2006248649A1 (en) 2006-11-23
MX2007014405A (es) 2008-04-21
ZA200710277B (en) 2009-03-25
CN101218232A (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
EA200702468A1 (ru) Новые производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA200702469A1 (ru) Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA200702471A1 (ru) Новые гетероциклические соединения в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
DE602005025672D1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
EA201070143A1 (ru) Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
DK1948606T3 (da) 3, 5-disubstituerede phenyl-piperidiner som modulatorer af dopaminneurotransmission
DE602004017213D1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
DE602006017209D1 (de) Carbamat-derivate als positive allosterische modulatoren von metabotropischen glutamat-rezeptoren
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
EA200701758A1 (ru) Замещённые арильные производные 1,4-пиразина
EA200970573A1 (ru) Агенты, усиливающие действие амра-рецепторов
UA92495C2 (ru) Замещенные производные оксадиазола как положительные аллостерические модуляторы метаботропных глутаматных рецепторов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU